ibotenic acid has been researched along with Parkinson Disease in 8 studies
Ibotenic Acid: A neurotoxic isoxazole (similar to KAINIC ACID and MUSCIMOL) found in AMANITA mushrooms. It causes motor depression, ataxia, and changes in mood, perceptions and feelings, and is a potent excitatory amino acid agonist.
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Although it is known that Parkinson's disease results from a loss of dopaminergic neurons in the substantia nigra, the resulting alterations in activity in the basal ganglia responsible for parkinsonian motor deficits are still poorly characterized." | 1.28 | Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. ( Bergman, H; DeLong, MR; Wichmann, T, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (25.00) | 18.7374 |
| 1990's | 3 (37.50) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, L | 1 |
| Liu, J | 1 |
| Zhang, QJ | 1 |
| Feng, JJ | 1 |
| Gui, ZH | 1 |
| Ali, U | 1 |
| Wang, Y | 1 |
| Fan, LL | 1 |
| Hou, C | 1 |
| Wang, T | 1 |
| Gonzalez, D | 1 |
| Miyamoto, O | 1 |
| Touge, T | 1 |
| Sumitani, K | 1 |
| Kuriyama, S | 1 |
| Itano, T | 1 |
| Jonsson, G | 1 |
| Baunez, C | 1 |
| Nieoullon, A | 1 |
| Amalric, M | 1 |
| Luquin, MR | 1 |
| Obeso, JA | 1 |
| Laguna, J | 1 |
| Guillén, J | 1 |
| Martínez-Lage, JM | 1 |
| Carvalho, GA | 1 |
| Nikkhah, G | 1 |
| Bergman, H | 1 |
| Wichmann, T | 1 |
| DeLong, MR | 1 |
| Hinzen, D | 1 |
| Hornykiewicz, O | 1 |
| Kobinger, W | 1 |
| Pichler, L | 1 |
| Pifl, C | 1 |
| Schingnitz, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Dual Frequency, Dual Region Deep Brain Stimulation of the Subthalamic Nucleus in Parkinson's Disease[NCT04650932] | 10 participants (Anticipated) | Interventional | 2022-10-22 | Recruiting | |||
| NMDA-Receptor Blockade With Eliprodil in Parkinson's Disease[NCT00001929] | Phase 2 | 20 participants | Interventional | 1999-03-31 | Completed | ||
| Can Subthreshold Transcranial Magnetic Stimulation (rTMS) to Motor Cortex and/or to Supplementary Motor Area (SMA) Improve Performance of Complex Motor Sequences in Parkinson's Disease?[NCT00001665] | 12 participants | Observational | 1997-01-31 | Completed | |||
| Convection Enhanced Delivery of Muscimol to Study the Pathophysiology Underlying the Clinical Features of Parkinson's Disease[NCT00921128] | Phase 1 | 0 participants (Actual) | Interventional | 2009-06-02 | Withdrawn | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for ibotenic acid and Parkinson Disease
| Article | Year |
|---|---|
Chemical neurotoxins as denervation tools in neurobiology.
Topics: 5,6-Dihydroxytryptamine; 5,7-Dihydroxytryptamine; Animals; Benzylamines; Brain; Catecholamines; Dene | 1980 |
7 other studies available for ibotenic acid and Parkinson Disease
| Article | Year |
|---|---|
Alterations of emotion, cognition and firing activity of the basolateral nucleus of the amygdala after partial bilateral lesions of the nigrostriatal pathway in rats.
Topics: Action Potentials; Adrenergic Agents; Amygdala; Animals; Antiparkinson Agents; Apomorphine; Behavior | 2011 |
Unilateral ibotenic acid lesions of the prefrontal cortex reduce rotational behavior in 6-hydroxydopamine-lesioned rats.
Topics: Adrenergic Agents; Animals; Behavior, Animal; Disease Models, Animal; Excitatory Amino Acid Agonists | 2006 |
In a rat model of parkinsonism, lesions of the subthalamic nucleus reverse increases of reaction time but induce a dramatic premature responding deficit.
Topics: Animals; Conditioning, Psychological; Corpus Striatum; Ibotenic Acid; Male; Motor Activity; Parkinso | 1995 |
The AMPA receptor antagonist NBQX does not alter the motor response induced by selective dopamine agonists in MPTP-treated monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Ac | 1993 |
Subthalamic nucleus lesions are neuroprotective against terminal 6-OHDA-induced striatal lesions and restore postural balancing reactions.
Topics: Animals; Cell Count; Corpus Striatum; Female; Functional Laterality; Ibotenic Acid; Models, Animal; | 2001 |
Reversal of experimental parkinsonism by lesions of the subthalamic nucleus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Chlorocebus aethiops; Disease Models, | 1990 |
Reversal of experimental parkinsonism by lesions of the subthalamic nucleus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Chlorocebus aethiops; Disease Models, | 1990 |
Reversal of experimental parkinsonism by lesions of the subthalamic nucleus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Chlorocebus aethiops; Disease Models, | 1990 |
Reversal of experimental parkinsonism by lesions of the subthalamic nucleus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Chlorocebus aethiops; Disease Models, | 1990 |
Reversal of experimental parkinsonism by lesions of the subthalamic nucleus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Chlorocebus aethiops; Disease Models, | 1990 |
Reversal of experimental parkinsonism by lesions of the subthalamic nucleus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Chlorocebus aethiops; Disease Models, | 1990 |
Reversal of experimental parkinsonism by lesions of the subthalamic nucleus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Chlorocebus aethiops; Disease Models, | 1990 |
Reversal of experimental parkinsonism by lesions of the subthalamic nucleus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Chlorocebus aethiops; Disease Models, | 1990 |
Reversal of experimental parkinsonism by lesions of the subthalamic nucleus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Chlorocebus aethiops; Disease Models, | 1990 |
Reversal of experimental parkinsonism by lesions of the subthalamic nucleus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Chlorocebus aethiops; Disease Models, | 1990 |
Reversal of experimental parkinsonism by lesions of the subthalamic nucleus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Chlorocebus aethiops; Disease Models, | 1990 |
Reversal of experimental parkinsonism by lesions of the subthalamic nucleus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Chlorocebus aethiops; Disease Models, | 1990 |
Reversal of experimental parkinsonism by lesions of the subthalamic nucleus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Chlorocebus aethiops; Disease Models, | 1990 |
Reversal of experimental parkinsonism by lesions of the subthalamic nucleus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Chlorocebus aethiops; Disease Models, | 1990 |
Reversal of experimental parkinsonism by lesions of the subthalamic nucleus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Chlorocebus aethiops; Disease Models, | 1990 |
Reversal of experimental parkinsonism by lesions of the subthalamic nucleus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Chlorocebus aethiops; Disease Models, | 1990 |
The dopamine autoreceptor agonist B-HT 920 stimulates denervated postsynaptic brain dopamine receptors in rodent and primate models of Parkinson's disease: a novel approach to treatment.
Topics: Animals; Azepines; Brain Chemistry; Drug Interactions; Ibotenic Acid; Macaca mulatta; Male; Mice; Mi | 1986 |